An interventional study of Personal Patient Profile - Prostate (P3P) and Standard prostate cancer information websites in Prostate Cancer, sponsored by Dana-Farber Cancer Institute. Completed at 4 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-31.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Other
The purpose of this study is to determine whether using the P3P website can increase decisional preparation and satisfaction, and decrease decisional conflict, in men deciding how to manage early stage prostate cancer.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's enrollment of 392 is above the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Dana-Farber Cancer Institute is the lead sponsor of 813 studies on the registry; 124 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 77 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Behavioral: Standard prostate cancer information websites
Behavioral: Personal Patient Profile - Prostate (P3P)
Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
Decisional conflict
O'Connor, 1995, Decisional conflict scale
Time frame: Change from baseline to 6-months
Preparation for decision making
Graham and O'Connor, 1995, Preparation for decision making scale
Time frame: 1-month after study entry
Satisfaction with decision
Holmes-Rovner et al, 1996, Satisfaction with decision scale
Time frame: 6-months after study entry
Concordance of care choice selected with self-reported influential personal preferences
Odds ratio of selecting a care option for prostate cancer concordant with avoiding prioritized side effects (XBRT or brachytherapy if concerned with sexual function; prostatectomy if concerned with bowel function; active surveillance if concerned with sexual, bowel, and/or bladder function; any treatment if not concerned with any side effect).
Time frame: 6-months from study entry
Net cost and benefit of the intervention
Cost to the patient will be measured in hours valued according to patient work status, income, and use of time. Benefit will be measured with Willingness to pay.
Time frame: 1-week after study entry
Time to treatment decision
Duration (in days) from pre-decision baseline questionnaire until patient decides on a care option for prostate cancer, either an active treatment type or active surveillance. Measured by patient recall at 6-months.
Time frame: 6-months from study entry
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute